Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Non-Current Assets (2022 - 2025)

Corvus Pharmaceuticals has reported Non-Current Assets over the past 4 years, most recently at $1.0 million for Q3 2025.

  • Quarterly results put Non-Current Assets at $1.0 million for Q3 2025, down 25.11% from a year ago — trailing twelve months through Sep 2025 was $1.0 million (down 25.11% YoY), and the annual figure for FY2024 was $1.3 million, down 7.78%.
  • Non-Current Assets for Q3 2025 was $1.0 million at Corvus Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Over the last five years, Non-Current Assets for CRVS hit a ceiling of $1.8 million in Q1 2022 and a floor of $1.0 million in Q3 2025.
  • Median Non-Current Assets over the past 4 years was $1.3 million (2024), compared with a mean of $1.4 million.
  • Biggest five-year swings in Non-Current Assets: grew 0.98% in 2024 and later dropped 25.11% in 2025.
  • Corvus Pharmaceuticals' Non-Current Assets stood at $1.7 million in 2022, then dropped by 13.62% to $1.4 million in 2023, then dropped by 7.78% to $1.3 million in 2024, then fell by 23.63% to $1.0 million in 2025.
  • The last three reported values for Non-Current Assets were $1.0 million (Q3 2025), $1.1 million (Q2 2025), and $1.2 million (Q1 2025) per Business Quant data.